Pfizer (PFE) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
PFIZER REPORTS SECOND-QUARTER 2016 RESULTS
August 2, 2016 6:45 AM EDTSecond-Quarter 2016 Revenues of $13.1 Billion, Reflecting 13% Operational Growth Driven by the Inclusion of Legacy Hospira Operations and 9% Operational Growth from Pfizer Innovative Health Second-Quarter 2016 Revenues for Pfizer Standalone (Excluding Legacy Hospira) of $12.0 Billion, Reflecting 4% Operational Growth Second-Quarter 2016 Reported Diluted EPS(1) of $0.33, Adjusted Diluted EPS(2) of $0.64 Reaffirmed 2016 Financial Guidance for Revenues and Adjusted Diluted EPS(2)
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2016 and reaffirmed its 2016 financial guidance for Revenues and Adjusted Diluted EPS(2).
... More